-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Summit Therapeutics, Lowers Price Target to $33

Benzinga·11/16/2026 13:26:47
Listen to the news
Evercore ISI Group analyst Cory Kasimov maintains Summit Therapeutics (NASDAQ:SMMT) with a Outperform and lowers the price target from $34 to $33.